POA
ARRY

Pergamon Offshore Advisors’s Array Biopharma Inc ARRY Stock Holding History

Pergamon Offshore Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-13,305
Closed -$96K – 213
2015
Q2 		$96K Buy
+13,305
New +$98.2K 0.1% 159

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pergamon Offshore Advisors's ARRY Position: Q3 2015 in Review

Pergamon Offshore Advisors sold out of Array Biopharma Inc (ARRY) in Q3 2015, closing a stake of 13,305 shares — an estimated $96K sold.

Pergamon Offshore Advisors first reported a position in ARRY in Q2 2015 and held it in 1 quarter. The position peaked at $96K in Q2 2015. 157 funds tracked by Wall St. Rank hold ARRY as of Q3 2015.

  • Pergamon Offshore Advisors reported no remaining Array Biopharma Inc position as of Q3 2015 after selling out during the quarter.
  • Pergamon Offshore Advisors sold 13,305 Array Biopharma Inc shares in Q3 2015, an estimated $96K.
  • Pergamon Offshore Advisors first reported a position in Array Biopharma Inc in Q2 2015 and held it in 1 quarter.
  • Pergamon Offshore Advisors's Array Biopharma Inc position peaked at $96K in Q2 2015.
  • 157 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2015.

Based on Pergamon Offshore Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.